Business

Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a...

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug...

New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for...

Now part of Rhelion Life Sciences, Canadian pharmaceutical developer Filament Health is supplying naturally derived psilocybin for clinical research worldwide,...

The Australian psychedelic-assisted therapy provider has reported record quarterly revenue of $1.42 million, expanded its national clinic network and received...

US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity...

Canadian pharmaceutical manufacturer Optimi Health has appointed experienced pharmaceutical executive Adrian Jones to lead its Australian operations, with a focus...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of...

Early clinical data presented at the ECNP Congress show predictable psychedelic effects and measurable changes in brain activity, as the...